dr. marcia brose discusses lenvatinib as a new option in dtc
Published 9 years ago • 666 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:23
dr. brose discusses lenvatinib for the treatment of patients with thyroid cancer
-
2:47
dr. brose discusses lenvatinib and sorafenib in differentiated thyroid cancer
-
1:10
dr. marcia brose on lenvatinib in differentiated thyroid cancer
-
1:05
dr. brose on unique elements of the lenvatinib trial
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
9:03
sequencing therapies for differentiated thyroid cancer
-
6:57
tki therapy for advanced thyroid cancer
-
6:06
living with thyroid cancer: the rai-refractory patient
-
1:02
dr. brose discusses updated overall survival analysis of the decision trial
-
1:18
dr. marcia brose on sorafenib in radioactive iodine-resistant thyroid cancer
-
1:56
dr. brose on vandetanib for differentiated thyroid cancer
-
0:57
dr. brose describes the decision trial
-
2:15
effect of age on lenvatinib on os for pts w/ 131i-refractory thyroid cancer
-
8:01
systemic therapy for rai-refractory dtc
-
4:31
phase ii study of everolimus and sorafenib in pts with metastatic differentiated thyroid cancer
-
5:58
role of the endocrinologist in rai-refractory thyroid cancer
-
1:26
novel treatment strategies for braf v600e-mutant nsclc
-
2:31
neoadjuvant therapy with trametinib and dabrafenib in high risk resectable braf-mutant melanoma
-
6:05
determining treatment for rai-refractory thyroid cancer